This project aims to develop advanced lipid-based nanocarriers functionalized with a lipid-conjugated peptide tag (pTag) for targeted drug delivery and immune activation. The system enables precise delivery of therapeutic payloads to CD40-expressing antigen-presenting cells by utilising Strike Pharma’s proprietary bispecific antibody technology, which binds both CD40 and the pTag.

By incorporating pTag into liposomes, reconstituted high-density lipoproteins (rHDL) nanodiscs, and lipid nanoparticles (LNPs), we establish a modular delivery platform adaptable to various cargo types, including mRNA, peptides, and small molecules. The pTag is anchored using DSPE-PEG-maleimide lipids, ensuring stable surface presentation and high-affinity antibody binding.

The structural characterization of the advanced nanocarriers will be performed using cryogenic transmission electron microscopy (cryo-TEM) and small angle X-ray scattering (SAXS), while the functional interaction between the nanocarrier and antibody will be evaluated using quartz crystal microbalance with dissipation monitoring (QCM-D) and surface plasmon resonance (SPR).

This cross-disciplinary collaboration between Malmö University, MAX IV Laboratory, the University of Copenhagen, and Strike Pharma integrates expertise in nanomedicine, structural biology, nanoscience, and immunotherapy to create a next-generation targeted delivery system.